Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MGTX logo MGTX
Upturn stock ratingUpturn stock rating
MGTX logo

MeiraGTx Holdings PLC (MGTX)

Upturn stock ratingUpturn stock rating
$6.52
Last Close (24-hour delay)
Profit since last BUY-1.51%
upturn advisory
Consider higher Upturn Star rating
BUY since 10 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: MGTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $27.5

1 Year Target Price $27.5

Analysts Price Target For last 52 week
$27.5Target price
Low$3.85
Current$6.52
high$8.75

Analysis of Past Performance

Type Stock
Historic Profit -58.34%
Avg. Invested days 29
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 531.22M USD
Price to earnings Ratio -
1Y Target Price 27.5
Price to earnings Ratio -
1Y Target Price 27.5
Volume (30-day avg) 5
Beta 1.18
52 Weeks Range 3.85 - 8.75
Updated Date 06/29/2025
52 Weeks Range 3.85 - 8.75
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.31

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2159.71%

Management Effectiveness

Return on Assets (TTM) -37.28%
Return on Equity (TTM) -216.14%

Valuation

Trailing PE -
Forward PE 1.61
Enterprise Value 547980983
Price to Sales(TTM) 15.39
Enterprise Value 547980983
Price to Sales(TTM) 15.39
Enterprise Value to Revenue 15.88
Enterprise Value to EBITDA -3.29
Shares Outstanding 80365400
Shares Floating 36569453
Shares Outstanding 80365400
Shares Floating 36569453
Percent Insiders 24.27
Percent Institutions 60.04

Analyst Ratings

Rating 3
Target Price 27.5
Buy 2
Strong Buy 3
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

MeiraGTx Holdings PLC

stock logo

Company Overview

overview logo History and Background

MeiraGTx Holdings PLC is a clinical-stage gene therapy company founded in 2015. They focus on developing novel gene therapies for serious diseases. The company has collaborations with various academic and industry partners to advance its pipeline.

business area logo Core Business Areas

  • Gene Therapy Development: MeiraGTx focuses on developing and manufacturing gene therapies for a range of diseases.
  • Ophthalmology: Developing gene therapies for inherited retinal diseases.
  • Salivary Gland Diseases: Developing gene therapies for radiation-induced xerostomia.
  • Neurodegenerative Diseases: Developing gene therapies for neurological disorders.

leadership logo Leadership and Structure

Alexandria Forbes serves as the President and CEO. The company operates with a focus on research and development, clinical trials, and manufacturing.

Top Products and Market Share

overview logo Key Offerings

  • AAV2-hAQP1: Gene therapy for radiation-induced xerostomia. Market share information is not publicly available at this early stage of drug development. Competitors include companies developing supportive care treatments for xerostomia.
  • Botaretigene Sparoparvovec (AAV2-RPGR): Gene therapy candidate for X-linked retinitis pigmentosa (XLRP). Market share unavailable as it's still in development. Competitors include other companies pursuing gene therapies for XLRP.

Market Dynamics

industry overview logo Industry Overview

The gene therapy industry is rapidly growing, with advancements in technology and increasing regulatory approvals. It's characterized by high R&D costs, long development timelines, and significant potential for treating genetic diseases.

Positioning

MeiraGTx is positioned as a specialized gene therapy company with a focus on ophthalmology, salivary gland diseases, and neurodegenerative disorders. Competitive advantages include proprietary technologies and collaborations.

Total Addressable Market (TAM)

The total addressable market for gene therapies is estimated to reach billions of dollars. MeiraGTx is targeting specific rare disease markets, allowing it to address niche segments within the broader gene therapy market. The exact TAM for their target indications is evolving based on clinical advancements and regulatory approvals.

Upturn SWOT Analysis

Strengths

  • Strong IP portfolio
  • Experienced management team
  • Proprietary manufacturing capabilities
  • Strategic collaborations

Weaknesses

  • Limited commercialized products
  • High R&D expenses
  • Dependence on clinical trial outcomes
  • Relatively small market capitalization

Opportunities

  • Expansion of pipeline through strategic partnerships
  • Regulatory approvals for key product candidates
  • Technological advancements in gene therapy
  • Increased investment in gene therapy research

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from larger pharmaceutical companies
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • SPHR
  • VRTX
  • BLUE

Competitive Landscape

MeiraGTx operates in a competitive landscape with both established pharmaceutical companies and emerging biotech firms focused on gene therapy. Advantages include its specialized focus and proprietary technology, while disadvantages include its smaller size and limited resources compared to larger competitors.

Growth Trajectory and Initiatives

Historical Growth: MeiraGTx has shown revenue growth primarily through collaboration agreements and milestone payments.

Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary based on pipeline progress.

Recent Initiatives: Recent initiatives include advancing clinical trials for key product candidates and expanding manufacturing capabilities.

Summary

MeiraGTx is a clinical-stage gene therapy company with a promising pipeline, but it's also operating with substantial losses due to high R&D costs. Revenue is growing through partnerships, but success hinges on positive clinical trial results and regulatory approvals. The company needs to effectively manage its cash flow and navigate the competitive gene therapy landscape to realize its full potential. Their pipeline and focus on genetic diseases holds strong promise.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Data may be subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About MeiraGTx Holdings PLC

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2018-06-08
CEO, President & Director Dr. Alexandria Forbes Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 372
Full time employees 372

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.